Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
暂无分享，去创建一个
O. Fiala | S. Salah | J. Bellmunt | F. Calabrò | R. Kanesvaran | E. Seront | J. Ansari | R. Zakopoulou | Z. Küronya | M. Rizzo | V. Mollica | J. Kopecký | H. Abahssain | A. Martignetti | J. Molina-Cerrillo | F. Massari | R. M. Kopp | M. Dionese | J. Landmesser | Matteo Santoni | Camillo Porta | Hideki Takeshita | Renate Pichler | Enrique Grande | Deniz Tural | Jakub Kucharz | D. Santini | J. C. Tapia | Elaine T. Lam | Robert Kemp